Cooley advised RAPT Therapeutics, while Davis Polk advised the joint book-running managers in the offering. with a $143.7 million SEC-registered follow-on offering of 4,356,060 shares of…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now